MII IG Kerndatensatz-Modul Biobank
2027.0.0-ballot - Germany

This page is part of the MII IG Kerndatensatz-Modul Biobank (v2027.0.0-ballot: 2027 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Inhaltsverzeichnis

Für die aktuelle Seite ist keine Übersetzung verfügbar, daher wurde sie in der Standardsprache dargestellt.

.. 0 Table of Contents
... 1 Home
... 2 Guidance
.... 2.1 Guidance for Researchers
.... 2.2 Guidance for Implementers
.... 2.3 UML Diagrams
.... 2.4 Glossary
... 3 Security and Privacy
... 4 Profiles
... 5 Extensions
... 6 Capability Statements
... 7 Logical Models
... 8 Value Sets
... 9 Code Systems
... 10 Examples
... 11 Downloads
... 12 Changelog
... 13 Metadata Overview
... 14 Versioning
... 15 MII ImplementationGuide Resource
... 16 Translation Information
... 17 Artifacts Summary
.... 17.1 MII CPS Biobank CapabilityStatement
.... 17.2 mii-sp-biobank-infektiositaetsstatus
.... 17.3 mii-sp-biobank-specimen-feature
.... 17.4 mii-sp-biobank-specimen-focus
.... 17.5 MII_LM_Biobank
.... 17.6 MII PR Biobank Observation DNA Konzentration
.... 17.7 MII PR Biobank Observation Karyotyp
.... 17.8 MII PR Biobank Observation Morphologie
.... 17.9 MII PR Biobank Observation Proliferation
.... 17.10 MII PR Biobank Observation Qualitätsprüfung
.... 17.11 MII PR Biobank Observation Wachstumstyp
.... 17.12 MII PR Biobank Organization Sammlung Biobank
.... 17.13 MII PR Biobank Specimen Bioprobe
.... 17.14 MII PR Biobank Specimen Bioprobe Core
.... 17.15 MII PR Biobank Specimen Zellinie Organoid
.... 17.16 MII PR Biobank Substance Additiv
.... 17.17 MII EX Biobank Anzahl Aliquots
.... 17.18 MII EX Biobank Anzahl Passagen
.... 17.19 MII EX Biobank Diagnose
.... 17.20 MII EX Biobank Ebene
.... 17.21 MII EX Biobank Einstellung Blutversorgung
.... 17.22 MII EX Biobank Feature R5
.... 17.23 MII EX Biobank Infektiositätsstatus
.... 17.24 MII EX Biobank Kulturprotokoll
.... 17.25 MII EX Biobank Rolle des Kontaktes
.... 17.26 MII EX Biobank Temperaturbedingungen
.... 17.27 MII EX Biobank Verwaltende Organisation
.... 17.28 MII EX Biobank Zelllinien-Modifikation
.... 17.29 MII VS Biobank Biosafety-Level Einstufung [SNOMED CT]
.... 17.30 MII VS Biobank BodyStructures SCT
.... 17.31 MII VS Biobank Cellinie Morphology SCT
.... 17.32 MII VS Biobank Cellline Modification CLO
.... 17.33 MII VS Biobank Containertyp SCT
.... 17.34 MII VS Biobank DNA Concentration Units UCUM
.... 17.35 MII VS Biobank Karyotyp SCT
.... 17.36 MII VS Biobank Laboratory Procedure SCT
.... 17.37 MII VS Biobank Probenart SCT
.... 17.38 MII VS Biobank Probenebene
.... 17.39 MII VS Biobank Proliferation Zellinie
.... 17.40 MII VS Biobank Substance Additive
.... 17.41 MII VS Biobank Wachstumpstyp CLO
.... 17.42 MII CS Biobank Contact Type
.... 17.43 MII CS Biobank Probenebene
.... 17.44 MII CM Biobank Fixation Type SPREC 4.0 SCT
.... 17.45 MII CM Biobank Long-Term Storage SPREC 4.0 SCT
.... 17.46 MII CM Biobank Primary Container SPREC 4.0 SCT
.... 17.47 MII CM Biobank Sample Type SPREC 4.0 SCT
.... 17.48 Biobank Musterstadt
.... 17.49 Buffy-Coat Aliquotgruppe
.... 17.50 Buffy-Coat Einzelaliquot 50 µl
.... 17.51 Buffy-Coat Einzelaliquot 50 µl
.... 17.52 CRISPR TP53 Knockout Protokoll
.... 17.53 DNA Aliquotgruppe
.... 17.54 DNA Konzentration Aliquot
.... 17.55 Heparin
.... 17.56 Karyotyp Organoid Lungenbiopsie
.... 17.57 Lungen-Organoid Kulturprotokoll
.... 17.58 Morphologie Organoid Lungenbiopsie
.... 17.59 Musterprobe flüssig
.... 17.60 Musterprobe Gewebe
.... 17.61 Mustersammlung
.... 17.62 Needle Biopsy Lung - Biobank
.... 17.63 Organoid Lungenbiopsie
.... 17.64 Plasma Aliquotgruppe
.... 17.65 Proliferation Organoid Lungenbiopsie
.... 17.66 Qualitätsprüfung Buffy-Coat Aliquotgruppe
.... 17.67 Qualitätsprüfung Plasma Aliquotgruppe
.... 17.68 Wachstumstyp Organoid Lungenbiopsie
.... 17.69 mii-param-biobank-manifest